Management of post-autologous transplant relapse in patients with T-cell lymphomas.
Olivier VeilleuxFrancisco SocolaSally AraiMatthew J FrankLaura JohnstonRobert LowskyJudith ShizuruEverett MeyerLori MufflyAndrew R RezvaniParveen ShirazSurbhi SidanaSaurabh DahiyaDavid B MiklosRobert S NegrinWen-Kai WengPublished in: American journal of hematology (2024)
Autologous hematopoietic cell transplantation (AHCT) is often used as a consolidation for patients with peripheral T-cell lymphomas (PTCLs) due to the poor prognosis associated with this heterogenous group of disorders. However, a significant number of patients will experience post-AHCT disease relapse. Here, we report a retrospective study of consecutive 124 patients with PTCLs who underwent AHCT from 2008 to 2020. With a median follow-up of 6.01 years following AHCT, 49 patients (40%) experienced disease relapse. As expected, more patients who were not in first complete remission experienced post-AHCT relapse. Following relapse, majority of the patients (70%) receiving systemic therapies intended as bridging to curative allogeneic HCT. However, only 18 (53%) patients eventually underwent allogeneic HCT. The estimated 3-year OS among patients proceeding to allogeneic HCT was 72% (95% CI 46%-87%). Our report details the pattern of post-AHCT relapse and the management of relapsed disease using different therapeutic modalities.
Keyphrases
- end stage renal disease
- poor prognosis
- bone marrow
- newly diagnosed
- ejection fraction
- chronic kidney disease
- stem cell transplantation
- prognostic factors
- peritoneal dialysis
- free survival
- acute lymphoblastic leukemia
- long non coding rna
- acute myeloid leukemia
- stem cells
- rectal cancer
- signaling pathway
- cell death
- platelet rich plasma
- patient reported
- ulcerative colitis